An Official Website of the United States Government
Company Information:
Name:
Enantigen Therapeutics, Inc
Address:
3805 OLD EASTON RD
DOYLESTOWN, PA 18902-8400
DOYLESTOWN, PA 18902-8400
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
http://enantigen.com
Phone:
(215) 589-6350
Award Totals:
Award List:
Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms
Award Year / Program / Phase:
2009 / STTR / Phase I
Agency / Branch:
DOD / DARPA
Research Institution:
New York University
Principal Investigator:
Neville R. Kallenbach, Professor of Chemistry
Award Amount:
$99,967.00
RI Contact:
Eric Bybee
Abstract:
This project addresses two pressing problems in treating bacterial infections: the emerging resistance against current antibiotics and the role of biofilm formation in these infections. Based ona successful lead dendrimerthat acts against a broad spectrum of MDR pathogens including A.baumannii, and… More
Development of a Therapy for Dengue Virus Infection
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Xiaodong Xu
Award Amount:
$282,480.00
Abstract:
DESCRIPTION (provided by applicant): This is a Phase I proposal to develop a new family of imino sugars, with break through , unprecedented, potency, for the treatment of dengue virus (DENV) infection. There is currently no effective treatment for disease
s caused by this virus and both the public… More
Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms
Award Year / Program / Phase:
2012 / STTR / Phase II
Agency / Branch:
DOD / ARMY
Research Institution:
New York University
Principal Investigator:
Xiaodong X. PhD, President – (215) 589-6350
Award Amount:
$738,292.00
RI Contact:
Richard Louth
Abstract:
This project builds on patterns derived from natural antimicrobial peptide sequences to develop novel compounds with better systemic activity, lower cytotoxicity and broader spectrum activity against multidrug resistant (MDR) pathogens. In Phase I and the
Development of Sulfamoylbenzamide Derivatives as Antiviral Agents against HBV Inf
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Xiaodong Xu – 215-589-6350
Award Amount:
$300,000.00
Abstract:
DESCRIPTION (provided by applicant): This is a proposal to develop newly discovered sulfamoylbenzamide derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as inhibitors of HBV pregenomic (pg) RNA encapsidation, a… More